Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial

Author:

Lu ShunORCID,Wang Jie,Yu Yan,Yu Xinmin,Hu Yanping,Ai Xinghao,Ma Zhiyong,Li Xingya,Zhuang Wu,Liu Yunpeng,Li Weidong,Cui Jiuwei,Wang Dong,Liao Wangjun,Zhou Jianying,Wang Zhehai,Sun Yuping,Qiu Xiusong,Gao Jie,Bao Yuanyuan,Liang Liang,Wang Mengzhao

Funder

BeiGene

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference20 articles.

1. The Global Cancer Observatory, WHO. Lung SOURCE: Globocan 2020. https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf. Accessed January 21, 2021.

2. Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer;Wu;Lung Cancer,2014

3. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer;Gandhi;N Engl J Med,2018

4. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial;West;Lancet Oncol,2019

5. National Comprehensive Cancer Network. Non-small cell lung cancer. version 6.2020). https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed June 15, 2020.

全球学者库

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"全球学者库"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前全球学者库共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2023 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3